Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical ...
Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission - - Strengthened ...
As of December 31, Senti Bio held cash and cash equivalents of $48.3M… “With initial data from the clinical trial of SENTI-202, we are ge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback